MDS Pharma Services has moved its central lab services to a new, larger facility in Beijing to meet growing demands from pharmaceutical and biotech companies conducting clinical trials in China.

With almost 25,000 sq. ft., the new facility offers a fivefold increase in testing capacity, four times the space to produce clinical trial kits, and a wider range of specialized clinical trial testing services, according to MDS. This new facility’s proximity to the Beijing airport also facilitates faster transportation of clinical trial samples.

Said MDS Pharma Services president David Spaight, “With many pharmaceutical and biotech companies now making China part of their global clinical trial programs, we recognized the need to expand our central lab operations and offer more diverse testing options.”

This new central lab facility specializes in molecular biology testing for infectious diseases, DNA banking and pharmacogenomics. It also offers enhanced molecular biology techniques, a microbiology lab and flow cytometry capabilities. MDS Pharma Services continues to offer project and data management from this new facility.

The company has been in China for more than 10 years, and was the first western CRO to own its facility in China.